7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

Genelux Corp.
(NASDAQ:GNLX) 

GNLX stock logo

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vac...

Founded: 2001
IPO Price: $6 (Jan 26, 2023)
Full Time Employees: 15
Sector: Healthcare
Industry: Biotechnology
Healthcare
Share this website to your friends
Genelux Days Payable Outstanding ttm (DPO)
202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 0197.02394.04591.07788.09985.111,182.131,379.16
Genelux Op Cashflow Per Share ttm
202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -0.76-0.65-0.54-0.43-0.32-0.22-0.110
Genelux Free Cashflow Per Share ttm
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -0.8-0.68-0.57-0.45-0.34-0.23-0.110
Genelux Cash Per Share ttm
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.160.330.490.650.810.981.14
Genelux P/S ratio ttm
202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 0222.42444.83667.25889.661,112.081,334.51,556.91
Genelux (GAAP) P/E ratio ttm
202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -40.73-34.91-29.09-23.27-17.45-11.64-5.820
Genelux P/B ratio ttm
202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -7.0727.6562.3897.1131.82166.54201.26235.98
No extra charts and metrics for this ticker.